Clearmind treats first AUD patients with CMND-100

Clearmind begins dosing Alcohol Use Disorder patients with CMND-100, advancing its non-hallucinogenic psychedelic-derived program into patient-stage testing.

Rhea-AI Filing Summary

Clearmind Medicine Inc. (CMND) reports a key clinical milestone, enrolling the first patients with Alcohol Use Disorder in its ongoing CMND-100 trial, with the first two patients treated at Hadassah Medical Center in Jerusalem. This is the first administration of CMND-100 to AUD patients, following prior multi-dose evaluation in healthy participants. The study is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of this non-hallucinogenic, psychedelic-derived candidate for AUD. Two paragraphs of the announcement are also incorporated by reference into several of Clearmind’s effective Form F-3 and Form S-8 registration statements.

Positive

• First AUD patients dosed with CMND-100, moving the asset from healthy-volunteer testing into patient-stage evaluation and advancing a core program in Clearmind’s pipeline.

Negative

• None.

Key Figures

Initial AUD patients treated with CMND-100: 2 patients Patent families: 19 patent families Granted patents: 32 granted patents +2 more

5 metrics

Initial AUD patients treated with CMND-100 2 patients First Alcohol Use Disorder patients enrolled and treated at Hadassah Medical Center in Jerusalem

Patent families 19 patent families Size of Clearmind’s intellectual property portfolio

Granted patents 32 granted patents Granted patents within Clearmind’s nineteen patent families

Form 6-K month September 2026 Reporting month for the foreign private issuer submission

Date of press release September 11, 2026 Date of the CMND-100 clinical enrollment announcement

Key Terms

neuroplastogen, pharmacokinetics, Alcohol Use Disorder, forward-looking statements, +1 more

5 terms

neuroplastogen medical

"advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment"

A neuroplastogen is a drug or compound designed to boost the brain’s ability to rewire and form new connections, enhancing recovery or adaptation after injury, stress, or disease. For investors, these molecules matter because they target underlying brain repair processes rather than just masking symptoms, offering the potential for durable benefits in conditions like depression, neurodegeneration, or cognitive decline—akin to giving a tired garden fresh tools to regrow and reshape itself.

pharmacokinetics medical

"designed to evaluate the safety, tolerability, pharmacokinetics and preliminary"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

Alcohol Use Disorder medical

"first patients with Alcohol Use Disorder in its ongoing clinical trial"

A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

clinical-stage medical

"a clinical-stage biopharmaceutical company advancing non-hallucinogenic"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind Medicine (CMND) announce in this Form 6-K?

Clearmind announced that it has enrolled and treated the first two patients with Alcohol Use Disorder in its ongoing CMND-100 clinical trial at Hadassah Medical Center in Jerusalem, marking the first administration of CMND-100 to AUD patients.

What is CMND-100 in Clearmind Medicine’s (CMND) pipeline?

CMND-100 is Clearmind’s proprietary psychedelic-based, non-hallucinogenic treatment candidate being developed for Alcohol Use Disorder. It has been tested at multiple doses in healthy participants and is now being evaluated in AUD patients for safety, tolerability, pharmacokinetics and preliminary efficacy.

What are the goals of the CMND-100 clinical trial reported by CMND?

The CMND-100 trial is designed to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with Alcohol Use Disorder, building on earlier multi-dose evaluations in healthy participants.

How many Alcohol Use Disorder patients has Clearmind treated so far with CMND-100?

Clearmind reports that the first two patients with Alcohol Use Disorder have been enrolled and treated with CMND-100 at Hadassah Medical Center in Jerusalem, representing the initial patient-stage use of this investigational therapy.

What intellectual property position does Clearmind Medicine (CMND) highlight?

Clearmind states that its intellectual property portfolio consists of nineteen patent families, including 32 granted patents, and that it intends to seek additional patents and may opportunistically acquire further intellectual property.

How is this CMND-100 update linked to Clearmind’s SEC registration statements?

Two paragraphs of the press release are incorporated by reference into Clearmind’s effective Form F-3 registration statements (multiple file numbers) and its Form S-8, making the clinical update part of those registration statements from the submission date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:09 AM Accepted by SEC EDGAR 09/14/2026 - 06:08 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on September 11, 2026, titled “Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial”.

The two paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: September 14, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

Exhibit 99.1

 

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorder (“AUD”) in its ongoing clinical trial evaluating CMND-100, the Company’s proprietary psychedelic-based treatment candidate for AUD.

The first two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first time CMND-100 is administered to a patient with AUD. To date, the Company has evaluated CMND-100 at multiple doses in healthy participants as part of its clinical development program.

“Our enrollment trajectory continues to build positively and treating the first Alcohol Use Disorder patients with CMND-100 represents a major step forward,” said Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind. “This achievement highlights the growing momentum behind the program and positions us well as we progress toward key clinical milestones that we believe can drive meaningful value for shareholders.

The clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with Alcohol Use Disorder.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated progress of the CMND-100 clinical trial, the achievement of future clinical milestones, the potential safety, tolerability, pharmacokinetic and efficacy results of CMND-100, the continued enrollment of patients in the trial, the development and commercialization potential of CMND-100, and the potential value that the program may create for shareholders. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "CLEARMIND ENROLLS FIRST PATIENTS WITH ALCOHOL USE DISORDE 8.3 KB